BCAX (Bicara Therapeutics) Asset Impairment Charge: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAX Bicara Therapeutics Inc BCAX
14 GF Score
Price $24.96
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Asset Impairment Charge?

Bicara Therapeutics BCAX +2.72% 14 Asset Impairment Charge is $0.00 Mil as of Jun. 2026. GuruFocus rates BCAX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Bicara Therapeutics's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Bicara Therapeutics Asset Impairment Charge Related Terms

Bicara Therapeutics Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Asset Impairment Charge Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
0.00 0.57 0.00 0.00

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BCAX
14GF Score
Bicara Therapeutics Inc BCAX
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Asset Impairment Charge of $0.00 Mil mean?
Bicara Therapeutics (BCAX) has a Asset Impairment Charge of $0.00 Mil as of Jun. 2026.
Is Bicara Therapeutics' Asset Impairment Charge too high?
Bicara Therapeutics' current Asset Impairment Charge is $0.00 Mil. Overall, Bicara Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Asset Impairment Charge compare to SLBT and DMRA?
Bicara Therapeutics' Asset Impairment Charge of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Bicara Therapeutics's current Asset Impairment Charge is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Asset Impairment Charge of $0.00 Mil. The current Asset Impairment Charge is $0.00 Mil. Bicara Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Asset Impairment Charge is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
14GF Score

Get the complete analysis for BCAX

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.96
Price